Invion Limited announced the appointment of three new members to the company's Scientific Advisory Board (SAB), which is expected to advance plans for clinical trials. Dr. Lynda Spelman, Associate Professor Louis Irving and Associate Professor Nathan Lawrentschuk ­ are consultants in skin cancer, lung cancer and urological cancer respectively. Skin cancer consultant Dr. Lynda Spelman is a specialist dermatologist with 26 years experience in dermatology and a special interest in clinical research trials. The appointment of Dr. Spelman is timely as Invion plans to have a gel formulation of its improved photosensitiser product IVX-P02 for the treatment of skin cancer ready in 2019 for testing in human clinical studies.